Zura Bio (NASDAQ:ZURA) Earns Outperform Rating from Analysts at Leerink Partners

Leerink Partners started coverage on shares of Zura Bio (NASDAQ:ZURA) in a report issued on Monday morning, Marketbeat.com reports. The firm issued an outperform rating and a $15.00 price objective on the stock.

ZURA has been the topic of several other reports. Piper Sandler reaffirmed an “overweight” rating and set a $26.00 price target on shares of Zura Bio in a research note on Thursday, September 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research report on Friday, October 18th. Finally, HC Wainwright reissued a “neutral” rating and set a $5.00 target price on shares of Zura Bio in a research report on Monday, October 21st. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Zura Bio currently has an average rating of “Moderate Buy” and a consensus target price of $16.75.

Zura Bio Price Performance

Shares of NASDAQ ZURA opened at $4.37 on Monday. Zura Bio has a 52 week low of $2.00 and a 52 week high of $6.35. The company’s 50-day moving average price is $4.16 and its 200 day moving average price is $4.08.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Equities research analysts forecast that Zura Bio will post -0.47 earnings per share for the current fiscal year.

Insider Activity at Zura Bio

In other Zura Bio news, Director Someit Sidhu sold 51,728 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total transaction of $200,187.36. Following the completion of the sale, the director now owns 2,085,418 shares in the company, valued at $8,070,567.66. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 22.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zura Bio

Several institutional investors have recently modified their holdings of ZURA. Point72 Asset Management L.P. bought a new position in shares of Zura Bio during the second quarter worth about $8,446,000. Great Point Partners LLC grew its position in shares of Zura Bio by 68.3% during the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock worth $16,248,000 after acquiring an additional 1,884,501 shares during the last quarter. Armistice Capital LLC lifted its holdings in Zura Bio by 53.2% in the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock worth $8,834,000 after purchasing an additional 876,000 shares during the period. Affinity Asset Advisors LLC acquired a new stake in Zura Bio in the first quarter worth about $1,157,000. Finally, Palumbo Wealth Management LLC acquired a new stake in Zura Bio in the third quarter worth about $156,000. Institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.